Amgen Inc (NASDAQ:AMGN)

115.46
Data as of Apr 17
 -0.08 / -0.07%
Today’s Change
94.15
Today|||52-Week Range
128.96
+1.21%
Year-to-Date
4 Reasons You Should Watch This Under-the-Radar Stock on Your Watchlist
6:31pm / MotleyFool.com
Eight pricey stocks haunting the Nasdaq
Apr 11 / Fortune
Emergent BioSolutions Gains on Trial News - Analyst Blog
Apr 17 / Zacks.com
Are Celgene and Amgen Undervalued By the Market?
Apr 11 / MotleyFool.com
Earnings Primer: What's on Deck for Amgen Inc. and Biogen Idec Inc.
Apr 17 / MotleyFool.com
Positive Data on Biogen/Sobi's Eloctate - Analyst Blog
Apr 11 / Zacks.com
Biotech Stock Mailbag: NeoStem, Gilead and the Importance of Big-Cap Biotech Earnings
Apr 17 / TheStreet.com
Encouraging Data from Bristol-Myers - Analyst Blog
Apr 11 / Zacks.com
Dynavax Starts Phase III Study on Heplisav-B - Analyst Blog
Apr 16 / Zacks.com
Stock Market News for April 11, 2014 - Market News
Apr 11 / Zacks.com
Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data -...
Apr 16 / Zacks.com
Market Hustle: Stock Futures Sink as JPMorgan's Profit Shrinks
Apr 11 / TheStreet.com
'Fast Money' Recap: Impressed by Yahoo!
Apr 16 / TheStreet.com
Halozyme Study Under Clinical Hold - Analyst Blog
Apr 10 / Zacks.com
Repros Completes Enrollment for Androxal Study - Analyst Blog
Apr 15 / Zacks.com
Gilead Announces Encouraging Sovaldi Data - Analyst Blog
Apr 10 / Zacks.com
Encouraging Results from Lexicon Candidate - Analyst Blog
Apr 15 / Zacks.com
Stock Market News for April 10, 2014 - Market News
Apr 10 / Zacks.com
FDA Nod for Merck's Grastek - Analyst Blog
Apr 15 / Zacks.com
3 Top-Ranked Biotech Stocks on the Rebound - Analyst Blog
Apr 10 / Zacks.com
Alimera/pSivida Seek FDA Approval for Iluvien - Analyst Blog
Apr 15 / Zacks.com
Oncolytics Reports Additional Data on Reolysin - Analyst Blog
Apr 09 / Zacks.com
Another Earnings Beat from J&J, View Up - Analyst Blog
Apr 15 / Zacks.com
Next-Gen Breast Cancer Drugs Offer Patients Hope
Apr 09 / MotleyFool.com
Are Biotechs Bad Medicine for the S&P 500?
Apr 15 / MotleyFool.com
Positive Trial Data Lifts Alkermes - Analyst Blog
Apr 09 / Zacks.com
Ambit Biosciences Slumps: AMBI Falls 13.0% in Session - Tale of the Tape
Apr 15 / Zacks.com
Sanofi to File for Lemtrada Approval Again - Analyst Blog
Apr 08 / Zacks.com
'Fast Money' Recap: Long on Financials
Apr 15 / TheStreet.com
Update on Merck's MK-3475 - Analyst Blog
Apr 08 / Zacks.com
Why Is Regeneron Pharmaceuticals, Inc. Bucking the Downtrend?
Apr 14 / MotleyFool.com
Questcor Buyout Shocks Short Sellers
Apr 08 / MotleyFool.com
Amgen's Conundrum
Apr 14 / MotleyFool.com
Encouraging Pre-Clinical Data from Celldex - Analyst Blog
Apr 08 / Zacks.com
Pipeline Progress at Coronado Biosciences - Analyst Blog
Apr 14 / Zacks.com
Intercept Pharma Prices 1M Share Offering, Shares Down - Analyst Blog
Apr 08 / Zacks.com
Amgen Inc (AMGN): Today's Featured Drugs Winner
Apr 14 / TheStreet.com
Halozyme Falls on Phase II Study Halt - Analyst Blog
Apr 08 / Zacks.com
Positive Results on Intercept Pharma's OCA - Analyst Blog
Apr 14 / Zacks.com
The Biggest Biotech Clinical Wins of the Week
Apr 08 / MotleyFool.com
Gilead Bucks Biotech Trend Thanks to Sovaldi News - Analyst Blog
Apr 14 / Zacks.com
Zacks Rank #1 Additions for Tuesday - Tale of the Tape
Apr 08 / Zacks.com
Stock Market News for April 14, 2014 - Market News
Apr 14 / Zacks.com
The Worst Biotech Failures of the Week
Apr 08 / MotleyFool.com
Encouraging Results on Gilead's Sovaldi - Analyst Blog
Apr 11 / Zacks.com
Momentum Slide to Continue for Netflix, Facebook? - Analyst Blog
Apr 07 / Zacks.com
3 Stocks Reiterated As A Buy: HAL, AMGN, BA
Apr 11 / TheStreet.com
Amgen's Oncology Candidate Disappoints - Analyst Blog
Apr 07 / Zacks.com
Qiagen Expands Personalized Healthcare Pipeline - Analyst Blog
Apr 11 / Zacks.com
Pfizer falls as treatment trial disappoints
Apr 07 / FT.com

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer LIBOR Warning: Neither BBA Enterprises Limited, nor the BBA LIBOR Contributor Banks, nor Reuters, can be held liable for any irregularity or inaccuracy of BBA LIBOR. Disclaimer. Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.